156 related articles for article (PubMed ID: 1899495)
1. Total androgen ablation: American experience.
Crawford ED; Nabors WL
Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
[No Abstract] [Full Text] [Related]
3. Total androgen ablation: Canadian experience.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
[TBL] [Abstract][Full Text] [Related]
4. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
5. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
Crawford ED; Goodman P; Blumenstein B
Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
[No Abstract] [Full Text] [Related]
6. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Collette L; Studer UE; Schröder FH; Denis LJ; Sylvester RJ
Prostate; 2001 Jun; 48(1):29-39. PubMed ID: 11391684
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
[TBL] [Abstract][Full Text] [Related]
8. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
[No Abstract] [Full Text] [Related]
9. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
[TBL] [Abstract][Full Text] [Related]
10. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
Matveev BP; Bukharkin BV
Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
[TBL] [Abstract][Full Text] [Related]
11. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
[TBL] [Abstract][Full Text] [Related]
12. Maximal androgen blockade in prostatic cancer.
Denis L
Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
[No Abstract] [Full Text] [Related]
13. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
16. The place and the results of monotherapy.
Bonnet P
Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
[No Abstract] [Full Text] [Related]
17. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
18. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
19. Complete androgen blockade for the treatment of prostate cancer.
Labrie F; Dupont A; Belanger A
Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
[No Abstract] [Full Text] [Related]
20. Newer methods of hormonal therapy for prostate cancer.
Soloway MS
Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
